Skip to main content
Erschienen in: Tumor Biology 6/2015

01.06.2015 | Research Article

MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition

verfasst von: Xiaolin Liu, Ruifen Dong, Zhijun Jiang, Yuyan Wei, Yingwei Li, Linxuan Wei, Hengzi Sun, Yinuo Li, Ning Yang, Qifeng Yang, Zhaojian Liu, Beihua Kong

Erschienen in: Tumor Biology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Ovarian cancer is a highly invasive cancer with poor prognosis. Previous studies have revealed lots of connections between the invasiveness and epithelial-mesenchymal transition (EMT), which is common during the progression of ovarian cancer. MDC1, a mediator of DNA damage checkpoint, has recently been implicated as a potential oncogene. Here, in this article, we studied the role of MDC1 in ovarian cancer metastasis. First, in tissue samples, we found that high expression level of MDC1 was correlated with poor prognosis. Furthermore, MDC1 overexpression in ovarian cancer cells significantly increased migration and invasion. In contrast, silencing MDC1 reversed these processes. Consistently, nude mice xenograft confirmed that silencing MDC1 suppressed tumor metastasis in vivo. We further demonstrated that MDC1 induced EMT through modulation EMT markers such as E-cadherin, N-cadherin, and vimentin. Taken together, our findings suggest that MDC1 promotes ovarian cancer metastasis through the induction of EMT.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.CrossRef Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.CrossRef
3.
Zurück zum Zitat De Craene B, Berx G. Regulatory networks defining emt during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.CrossRefPubMed De Craene B, Berx G. Regulatory networks defining emt during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.CrossRefPubMed
4.
Zurück zum Zitat Kim MK, Kim MA, Kim H, Kim YB, Song YS. Expression profiles of epithelial-mesenchymal transition-associated proteins in epithelial ovarian carcinoma. BioMed Res Int. 2014;2014:495754.PubMedPubMedCentral Kim MK, Kim MA, Kim H, Kim YB, Song YS. Expression profiles of epithelial-mesenchymal transition-associated proteins in epithelial ovarian carcinoma. BioMed Res Int. 2014;2014:495754.PubMedPubMedCentral
5.
Zurück zum Zitat Huang RY, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (emt) in epithelial ovarian cancer. Curr Drug Targets. 2012;13:1649–53.CrossRefPubMed Huang RY, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (emt) in epithelial ovarian cancer. Curr Drug Targets. 2012;13:1649–53.CrossRefPubMed
6.
Zurück zum Zitat Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291:59–66.CrossRefPubMed Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291:59–66.CrossRefPubMed
7.
Zurück zum Zitat Stucki M, Jackson SP. Mdc1/nfbd1: A key regulator of the DNA damage response in higher eukaryotes. DNA Repair. 2004;3:953–7.CrossRefPubMed Stucki M, Jackson SP. Mdc1/nfbd1: A key regulator of the DNA damage response in higher eukaryotes. DNA Repair. 2004;3:953–7.CrossRefPubMed
8.
Zurück zum Zitat Coster G, Goldberg M. The cellular response to DNA damage: A focus on mdc1 and its interacting proteins. Nucleus. 2010;1:166–78.CrossRefPubMed Coster G, Goldberg M. The cellular response to DNA damage: A focus on mdc1 and its interacting proteins. Nucleus. 2010;1:166–78.CrossRefPubMed
9.
Zurück zum Zitat Jungmichel S, Stucki M. Mdc1: The art of keeping things in focus. Chromosoma. 2010;119:337–49.CrossRefPubMed Jungmichel S, Stucki M. Mdc1: The art of keeping things in focus. Chromosoma. 2010;119:337–49.CrossRefPubMed
10.
Zurück zum Zitat Lou Z, Minter-Dykhouse K, Franco S, Gostissa M, Rivera MA, Celeste A, et al. Mdc1 maintains genomic stability by participating in the amplification of atm-dependent DNA damage signals. Mol Cell. 2006;21:187–200.CrossRefPubMed Lou Z, Minter-Dykhouse K, Franco S, Gostissa M, Rivera MA, Celeste A, et al. Mdc1 maintains genomic stability by participating in the amplification of atm-dependent DNA damage signals. Mol Cell. 2006;21:187–200.CrossRefPubMed
11.
Zurück zum Zitat Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. Mdc1 is a mediator of the mammalian DNA damage checkpoint. Nature. 2003;421:961–6.CrossRefPubMed Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. Mdc1 is a mediator of the mammalian DNA damage checkpoint. Nature. 2003;421:961–6.CrossRefPubMed
12.
Zurück zum Zitat Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. Mdc1 directly binds phosphorylated histone h2ax to regulate cellular responses to DNA double-strand breaks. Cell. 2005;123:1213–26.CrossRefPubMed Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. Mdc1 directly binds phosphorylated histone h2ax to regulate cellular responses to DNA double-strand breaks. Cell. 2005;123:1213–26.CrossRefPubMed
13.
Zurück zum Zitat d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194–8.CrossRefPubMed d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194–8.CrossRefPubMed
14.
Zurück zum Zitat Goldberg M, Stucki M, Falck J, D’Amours D, Rahman D, Pappin D, et al. Mdc1 is required for the intra-s-phase DNA damage checkpoint. Nature. 2003;421:952–6.CrossRefPubMed Goldberg M, Stucki M, Falck J, D’Amours D, Rahman D, Pappin D, et al. Mdc1 is required for the intra-s-phase DNA damage checkpoint. Nature. 2003;421:952–6.CrossRefPubMed
15.
Zurück zum Zitat Lou Z, Minter-Dykhouse K, Wu X, Chen J. Mdc1 is coupled to activated chk2 in mammalian DNA damage response pathways. Nature. 2003;421:957–61.CrossRefPubMed Lou Z, Minter-Dykhouse K, Wu X, Chen J. Mdc1 is coupled to activated chk2 in mammalian DNA damage response pathways. Nature. 2003;421:957–61.CrossRefPubMed
16.
Zurück zum Zitat Nakanishi M, Ozaki T, Yamamoto H, Hanamoto T, Kikuchi H, Furuya K, et al. Nfbd1/mdc1 associates with p53 and regulates its function at the crossroad between cell survival and death in response to DNA damage. J Biol Chem. 2007;282:22993–3004.CrossRefPubMed Nakanishi M, Ozaki T, Yamamoto H, Hanamoto T, Kikuchi H, Furuya K, et al. Nfbd1/mdc1 associates with p53 and regulates its function at the crossroad between cell survival and death in response to DNA damage. J Biol Chem. 2007;282:22993–3004.CrossRefPubMed
17.
Zurück zum Zitat Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12:587–98.CrossRefPubMed Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12:587–98.CrossRefPubMed
18.
Zurück zum Zitat Watanabe S, Watanabe K, Akimov V, Bartkova J, Blagoev B, Lukas J, et al. Jmjd1c demethylates mdc1 to regulate the rnf8 and brca1-mediated chromatin response to DNA breaks. Nat Struct Mol Biol. 2013;20:1425–33.CrossRefPubMed Watanabe S, Watanabe K, Akimov V, Bartkova J, Blagoev B, Lukas J, et al. Jmjd1c demethylates mdc1 to regulate the rnf8 and brca1-mediated chromatin response to DNA breaks. Nat Struct Mol Biol. 2013;20:1425–33.CrossRefPubMed
19.
Zurück zum Zitat Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, et al. Poly (adp-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem. 2014;289:20543–58.CrossRefPubMedPubMedCentral Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, et al. Poly (adp-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem. 2014;289:20543–58.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Yang Z, Bu Y, Wang C, Liu G, Song F. Growth inhibition, morphology change, and cell cycle alterations in nfbd1-depleted human esophageal cancer cells. Mol Cell Biochem. 2010;342:1–6.CrossRefPubMed Yang Z, Bu Y, Wang C, Liu G, Song F. Growth inhibition, morphology change, and cell cycle alterations in nfbd1-depleted human esophageal cancer cells. Mol Cell Biochem. 2010;342:1–6.CrossRefPubMed
21.
Zurück zum Zitat Yuan C, Bu Y, Wang C, Yi F, Yang Z, Huang X, et al. Nfbd1/mdc1 is a protein of oncogenic potential in human cervical cancer. Mol Cell Biochem. 2012;359:333–46.CrossRefPubMed Yuan C, Bu Y, Wang C, Yi F, Yang Z, Huang X, et al. Nfbd1/mdc1 is a protein of oncogenic potential in human cervical cancer. Mol Cell Biochem. 2012;359:333–46.CrossRefPubMed
22.
Zurück zum Zitat Ye Q, Chen L, Yin X, Liu YJ, Ji Q, Zhao E: Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathology oncology research. POR. 2014. Ye Q, Chen L, Yin X, Liu YJ, Ji Q, Zhao E: Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathology oncology research. POR. 2014.
23.
Zurück zum Zitat Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One. 2009;4:e6529.CrossRefPubMedPubMedCentral Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One. 2009;4:e6529.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Welcsh PL, King MC. Brca1 and brca2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705–13.CrossRefPubMed Welcsh PL, King MC. Brca1 and brca2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705–13.CrossRefPubMed
26.
Zurück zum Zitat Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12:801–17.CrossRefPubMed Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12:801–17.CrossRefPubMed
27.
Zurück zum Zitat Goodwin JF, Knudsen KE: Beyond DNA repair: DNA-pk function in cancer. Cancer discovery. 2014. Goodwin JF, Knudsen KE: Beyond DNA repair: DNA-pk function in cancer. Cancer discovery. 2014.
29.
Zurück zum Zitat Masutani M, Fujimori H. Poly (adp-ribosyl) ation in carcinogenesis. Mol Aspects Med. 2013;34:1202–16.CrossRefPubMed Masutani M, Fujimori H. Poly (adp-ribosyl) ation in carcinogenesis. Mol Aspects Med. 2013;34:1202–16.CrossRefPubMed
31.
Zurück zum Zitat Bartkova J, Horejsi Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, et al. DNA damage response mediators mdc1 and 53 bp1: Constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene. 2007;26:7414–22.CrossRefPubMed Bartkova J, Horejsi Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, et al. DNA damage response mediators mdc1 and 53 bp1: Constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene. 2007;26:7414–22.CrossRefPubMed
32.
Zurück zum Zitat Wang B, Zhang L, Qiu F, Fang W, Deng J, Zhou Y, et al. A newfound association between mdc1 functional polymorphism and lung cancer risk in chinese. PLoS One. 2014;9:e106794.CrossRefPubMedPubMedCentral Wang B, Zhang L, Qiu F, Fang W, Deng J, Zhou Y, et al. A newfound association between mdc1 functional polymorphism and lung cancer risk in chinese. PLoS One. 2014;9:e106794.CrossRefPubMedPubMedCentral
Metadaten
Titel
MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition
verfasst von
Xiaolin Liu
Ruifen Dong
Zhijun Jiang
Yuyan Wei
Yingwei Li
Linxuan Wei
Hengzi Sun
Yinuo Li
Ning Yang
Qifeng Yang
Zhaojian Liu
Beihua Kong
Publikationsdatum
01.06.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3063-5

Weitere Artikel der Ausgabe 6/2015

Tumor Biology 6/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.